NIH: U.S.-China Program for Biomedical Collaborative Research (2.21.19)

January 8, 2019
By: julie.harbin@duke.edu, Writer, DCI

U.S.-China Program for Biomedical Collaborative Research (R01 Clinical Trial Optional)

Funding Agency: National Institutes of Health

The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Chinese researchers in the areas of cancer, environmental health, heart disease, blood disorders, diseases of the eye and visual system, mental health, and neurological disorders. Partnering U.S. and Chinese investigators must work jointly to submit identical applications to NIH and National Natural Science Foundation of China (NSFC), respectively.  U.S. investigators must respond to the announcement from NIH, including the Chinese application as an attachment, and Chinese investigators must respond to a separate funding announcement from NSFC, including the NIH application as an attachment.  

Funding Amount: $750,000

Application budgets are limited to $150,000 annually in direct costs. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Application Deadlines:  
Letter of Intent Due Date: 30 days prior to the application
Application Due Date(s): February 21, 2019
AIDS Application Due Date(s): February 21, 2019

Eligibility: Faculty
Note: The Chinese collaborators must not be designated as PDs/PIs on the application in response to this FOA. 

For more information: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-009.html